Cancer Therapeutics in India: A Deep Patent Base with Few Commercial Players

What it is

Cancer therapeutics encompass a range of medical treatments designed to stop or slow cancer cell growth. The arsenal includes traditional chemotherapy, targeted therapies that attack specific proteins driving tumors, immunotherapies that harness the body’s immune system, and gene and cell therapies that modify a patient’s own cells to fight cancer.

Targeted therapies use small-molecule drugs or monoclonal antibodies to block molecules involved in tumor growth. Immunotherapies, such as checkpoint inhibitors, release brakes on immune cells, while CAR-T cell therapy engineers T cells to recognize and attack cancer. Gene therapy introduces genetic material to correct mutations or directly kill cancer cells. These modalities are shifting oncology from a one-size-fits-all approach to precision medicine.

The global market is projected to reach USD 700 billion by 2034 (DelveInsight), driven by rising incidence and a pipeline of novel agents. In India, the oncology treatment market is estimated at USD 2.88 billion in 2025 and could grow to USD 7.12 billion by 2032 (MarkNtel Advisors), underscoring the scale of the opportunity.

The value chain

• Research & Discovery: Basic cancer biology, target identification, and drug candidate discovery. Dominated by academic institutions and biotech startups. High defensibility through patents on novel targets and molecules.
• API Manufacturing: Production of active pharmaceutical ingredients (small molecules and biologics). Requires high potency and complex synthesis. India is a global hub for cost-competitive API supply, but high-end biologic APIs remain concentrated with specialized players.
• Drug Development & Clinical Trials: Preclinical and clinical testing managed by CROs and supported by CDMOs. India’s large patient pool and lower costs make it a growing destination for clinical trials, though regulatory timelines can be a hurdle.
• Manufacturing & Packaging: Large-scale production of finished drug products, including sterile injectables, oral solids, and cell/gene therapies. Cold chain logistics are critical for biologics. Margins are moderate, scale-driven.
• Distribution & Supply Chain: Wholesale distribution, specialty pharmacy, and cold chain delivery to hospitals. Low margin but essential for access. India’s fragmented distribution network presents both a challenge and an opportunity for tech-enabled logistics.
• Healthcare Providers: Hospitals, cancer centers, and specialty clinics that administer therapies. In India, a concentration of advanced centers in metros leaves tier-2/3 cities underserved, creating demand for decentralized care models.

Where it’s heading

• Immune checkpoint inhibitors are becoming first-line therapy across multiple tumor types, expanding the immunotherapy market (DelveInsight).
• CAR-T cell therapy and bispecific antibodies are rapidly gaining approvals for both hematologic and solid tumors, with manufacturing innovations aiming to reduce cost and complexity.
• Biomarker-driven precision oncology is integrating into standard care, enabling patient stratification and improving trial success rates.
• Biosimilars are expanding access to expensive biologics, particularly in India where affordability is paramount (India Oncology Market Analysis).
• India’s oncology market is forecast to grow at a 20% CAGR through 2030, driven by rising cancer incidence, an aging population, and expanding healthcare infrastructure (Oncology Market in India 2026-2030).
• Targeted drugs hold a 44% share of India’s cancer treatment market, with breast cancer as the largest segment by cancer type (MarkNtel Advisors). North India accounts for roughly 34% of revenue.

The opportunity in India

Our dataset maps 340 patents to cancer therapeutics, and the filing momentum is rising — a strong signal of inventive activity. Yet only 10 patent-holding startups appear in our data, and just 3 deep-tech companies explicitly reference cancer therapeutics in their profiles. This gap between patent output and commercial startup formation points to a significant white space.

The sparse startup landscape suggests that much of the innovation remains within academic labs or large pharma, with limited spin-off activity. For founders, this means less competition in building IP-backed ventures around novel targets, drug delivery platforms, or affordable biologics manufacturing. Investors can find early-stage opportunities where patent portfolios exist but haven’t been commercialized.

India’s strengths in API manufacturing, clinical trial services, and a growing domestic market create a fertile ground for deep-tech startups that can bridge the gap from lab to market. Areas like CAR-T manufacturing, AI-driven drug discovery, and biosimilar development are particularly ripe for new entrants.

India signal: patents, startups, capital

Patent stock: 340 patents matched to cancer therapeutics. Momentum is rising, with published filings increasing even before the last two years fully publish — a strong indicator of sustained R&D output.

Startup footprint: Our data identifies 10 patent-holding startups, including Aten Porus Lifesciences, Cashmir Biotech, and Chitkara Innovation Incubator Foundation. Separately, only 3 deep-tech companies in our dataset explicitly reference cancer therapeutics in their profiles — Vivfy Research, Precyte Innovations, and Dalom Biotech Innovations. This thin commercial layer relative to patent activity highlights a gap in translation.

Broader sector capital: The health-life-sciences sector has seen 973 companies raise a total of $2.6 billion, with a median raise of $1.0 million. Notable funded players in the sector include Enveda ($517M, series D+), Qure.ai ($130M, series D+), and Pandorum Technologies ($52.1M, series B). While these are not all cancer-focused, they illustrate the capital available for life-science innovation in India.

In our data

Sources

• Gene Therapy for Cancer Treatment: Past, Present and Future ↗
• Targeted Therapy for Cancer - NCI ↗
• How Cell and Gene Therapy Kills Cancer ↗
• Delivering the Full Value Chain for Oncology Clinical Trials ↗
• Transforming Life Sciences and Pharmaceutical Supply ... ↗
• Present And Future of Oncology: What Is Needed from API ... ↗
• Cancer Therapy Market Size, Forecast, Outlook, Companies ↗
• Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029 ↗